ASX:PXS Pharmaxis Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pharmaxis Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeA$0.09MA: A$0.09▼A$0.0952-Week Range N/AVolume721,139 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsEarningsInsider TradesHeadlines Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, liver, IPF, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Pharmaxis. Previous Next 2.4 Community Rank Outperform VotesPharmaxis has received 49 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPharmaxis has received 55 “underperform” votes. (Add your “underperform” vote.)Community SentimentPharmaxis has received 52.88% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pharmaxis and other stocks. Vote “Outperform” if you believe PXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PXS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPharmaxis does not currently pay a dividend.Dividend GrowthPharmaxis does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharmaxis insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolASX:PXS Previous Symbol CUSIPN/A CIKN/A Webwww.pharmaxis.com.au Phone+61-2-94547200Debt Debt-to-Equity Ratio569.81 Current Ratio3.59 Quick Ratio3.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.62 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.32 Book ValueA$0.00 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive PXS News and Ratings via Email Sign-up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Pharmaxis (ASX:PXS) Frequently Asked Questions How were Pharmaxis' earnings last quarter? Pharmaxis Ltd. (ASX:PXS) announced its earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. View Pharmaxis' earnings history. Who are some of Pharmaxis' key competitors? Some companies that are related to Pharmaxis include Antisense Therapeutics (ANP), Bayer (BAYN), HedgePath Pharmaceuticals (MAYNF), Mayne Pharma Group (MYX), Medical Developments International (MVP), Opthea (OPT), OTSUKA HOLDINGS/ADR (OTSKY), Patrys (PAB), Recce Pharmaceuticals (RCE), Roche (RHHVF), Sanofi (SNYNF), Sanofi (SAN), SINR PHAR/PAR VTG FPD 0.01 (SPH) and Vita Life Sciences (VLS). View all competitors. What other stocks do shareholders of Pharmaxis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmaxis investors own include Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Matinas BioPharma (MTNB), XPO Logistics (XPO), AIkido Pharma (AIKI), Senmiao Technology (AIHS) and Auckland International Airport (AIA). Who are Pharmaxis' key executives? Pharmaxis' management team includes the following people: Mr. Gary Jonathan Phillips, CEO & Director (Age 58)Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 63)Mr. Wolfgang G. Jarolimek B.Sc. Ph.D., Head of Drug Discovery (Age 55)Dr. Brett Charlton MBBS Ph.D., Medical Director (Age 63)Ms. Kristen Morgan BSc, PGDipBusAdmin, MMedSc, Officer of Alliance Management & Medical and Regulatory Affairs (Age 47) What is Pharmaxis' stock symbol? Pharmaxis trades on the ASX under the ticker symbol "PXS." How big of a company is Pharmaxis? Pharmaxis has a market capitalization of $0.00 and generates $12.62 million in revenue each year. Pharmaxis employs 64 workers across the globe. What is Pharmaxis' official website? The official website for Pharmaxis is www.pharmaxis.com.au. How can I contact Pharmaxis? Pharmaxis' mailing address is 20 Rodborough Rd, FRENCHS FOREST, NSW 2086, Australia. The company can be reached via phone at +61-2-94547200. This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
